Skip to main content

InvestorNewsBreaks – RYAH Group Inc. (CSE: RYAH) Announces MOU with Bazelet Pharma Ltd., Closing of Initial Tranche of Private Placement

RYAH Group (CSE: RYAH) today announced its entry into a memorandum of understanding (“MOU”) with Bazelet Pharma Ltd. and affiliates (together, “Bazelet”), the largest medical cannabis processing company in Israel, serving thousands of patients. According to the update, the collaboration is aimed at servicing Bazelet’s patients using RYAH Smart Inhalers and data analytics, once certified as a medical device in Israel, with the goal of providing safe and accurate patient inhalation therapies in plant medicine. “Bazelet brings extraordinary depth and expertise within a well-established and fast-growing medical cannabis market. We’re excited to be collaborating with Bazelet in bringing our smart inhaler and data analytics into this important region,” said Gregory Wagner, chief executive officer of RYAH.

In addition, RYAH provided an update to its previously announced non-brokered private placement of units of the company for aggregate gross proceeds of up to C$1,500,000, at an issue price of C$0.05 per unit (the “private placement”). As previously announced, each unit consists of (i) one Class A subordinate voting share of the company, and (ii) one share purchase warrant of the company (a “warrant”). Each warrant is exercisable for a period of 24 months at an exercise price of C$0.065. RYAH, on Jan. 21, 2022, closed the initial tranche of the private placement, with such tranche consisting of the issuance of an aggregate of 3,556,000 units for aggregate gross proceeds of C$177,800.

To view the full press releases, visit and

About RYAH Group Inc.

RYAH is a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry. Its robust artificial intelligence platform aggregates and correlates Health Insurance Portability and Accountability Act (“HIPAA”)-compliant patient data, intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is relevant for clinics, doctors, dispensaries and pharmaceutical companies and licensed processors (“LPs”) to monitor and manage formulation effects on patients and demographics. With a strong intellectual property portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation lifecycle. For more information, visit

NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office

InvestorWire is part of the InvestorBrandNetwork.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.